Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis

Autor: Shepherd, Emma L., Saborano, Raquel, Northall, Ellie, Matsuda, Kae, Ogino, Hitomi, Yashiro, Hiroaki, Pickens, Jason, Feaver, Ryan E., Cole, Banumathi K., Hoang, Stephen A., Lawson, Mark J., Olson, Matthew, Figler, Robert A., Reardon, John E., Nishigaki, Nobuhiro, Wamhoff, Brian R., Günther, Ulrich L., Hirschfield, Gideon, Erion, Derek M., Lalor, Patricia F.

Publikováno v: In JHEP Reports April 2021 3(2)

遺伝子改変動物を用いた脂肪酸受容体GPR40/FFAR1の生理的役割に関する研究

Autor: MATSUDA, Kae

2016
【要旨】

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::763dcafe0320b921066665b094e743f0
https://tsukuba.repo.nii.ac.jp/records/42665

Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis.

Autor: Shepherd EL; Centre for Liver and Gastroenterology Research and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Saborano R; Centre for Liver and Gastroenterology Research and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Northall E; Centre for Liver and Gastroenterology Research and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Matsuda K; Takeda Pharmaceuticals Cardiovascular and Metabolic Drug Discovery Unit, Kanagawa, Japan., Ogino H; Takeda Pharmaceuticals Cardiovascular and Metabolic Drug Discovery Unit, Kanagawa, Japan., Yashiro H; Takeda Pharmaceuticals Gastroenterology Drug Discovery Unit, Cambridge, MA, USA., Pickens J; Takeda Pharmaceuticals Gastroenterology Drug Discovery Unit, Cambridge, MA, USA., Feaver RE; HemoShear Therapeutics, Charlottesville, VA, USA., Cole BK; HemoShear Therapeutics, Charlottesville, VA, USA., Hoang SA; HemoShear Therapeutics, Charlottesville, VA, USA., Lawson MJ; HemoShear Therapeutics, Charlottesville, VA, USA., Olson M; HemoShear Therapeutics, Charlottesville, VA, USA., Figler RA; HemoShear Therapeutics, Charlottesville, VA, USA., Reardon JE; HemoShear Therapeutics, Charlottesville, VA, USA., Nishigaki N; Takeda Pharmaceuticals Cardiovascular and Metabolic Drug Discovery Unit, Kanagawa, Japan., Wamhoff BR; HemoShear Therapeutics, Charlottesville, VA, USA., Günther UL; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Hirschfield G; Centre for Liver and Gastroenterology Research and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.; Toronto Centre for Liver Disease, University of Toronto, Toronto General Hospital, Toronto, Canada., Erion DM; Takeda Pharmaceuticals Gastroenterology Drug Discovery Unit, Cambridge, MA, USA., Lalor PF; Centre for Liver and Gastroenterology Research and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Publikováno v: JHEP reports : innovation in hepatology [JHEP Rep] 2020 Nov 20; Vol. 3 (2), pp. 100217. Date of Electronic Publication: 2020 Nov 20 (Print Publication: 2021).